Oncology (all articles)
COVID-19 vaccine-linked adenopathies could mimic breast malignancies
2 Feb, 2021 | 01:17h | UTCCOVID-19 Vaccine-Linked Adenopathies Could Mimic Breast Malignancies – Diagnostic Imaging
Original Study: Unilateral axillary Adenopathy in the setting of COVID-19 vaccine – Clinical Imaging
Commentaries on Twitter
Important for radiologists to consider vaccine induced hyperplastic adenopathy in unilateral axillary adenopathy seen on #breastimaging post #COVID19Vaccine #COVID19
Read here https://t.co/7IizHgIzU0@NishiMehtaMD @KatiaDodelzon @KemiMDRad @WCMRadiology @BreastImaging
— Clinical Imaging (@CI_Journal) January 19, 2021
The COVID-19 vaccine may cause swollen lymph nodes that could be mistaken for breast malignancies. However, it's important not to postpone your vaccine or breast cancer screenings, researchers from @WCMRadiology and @WCMBreastCenter say. https://t.co/jLuVbA2rXL
— Weill Cornell Medicine (@WeillCornell) January 22, 2021
An analysis of contemporary oncology randomized clinical trials from low/middle-income vs. high-income countries
1 Feb, 2021 | 01:36h | UTCAn Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries – JAMA Oncology (free for a limited period)
ASCO Guideline: Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer
1 Feb, 2021 | 01:34h | UTC
Consensus statement recommends individualizing surveillance mammography for older patients after treatment for early-stage breast cancer
1 Feb, 2021 | 01:33h | UTCCommentaries: First Mammography Guidelines Released for Older Breast Cancer Survivors – Diagnostic Imaging AND New Surveillance Mammography Screening Guidelines Issued for Breast Cancer Survivors Aged 75 and Older – The ASCO Post
Radiation therapy for small-cell lung cancer: ASCO Guideline endorsement of an ASTRO Guideline
29 Jan, 2021 | 01:27h | UTC
Randomized trial: Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer
28 Jan, 2021 | 01:09h | UTC
Commentary on Twitter
? POP-RT P3 RCT in @ASCO_pubs
High-risk prostate cancer & pelvic LN risk ≥20% ➡️
-Prostate only
-Pelvic RTIG-IMRT w/ SIB
-50 Gy/25 fxn to Pelvis
-68 Gy to P+SV⬆️bFFS 95% v 81%
⬆️DFS ~90% v 77%
⬆️DMFS 96% v 89%
✅Low S/Ehttps://t.co/r6YjqWl8Cr#pcsm #radonc #oncoalert pic.twitter.com/d9EL02edcd— Mudit Chowdhary MD (@DrChowdharyMD) January 27, 2021
ASCO Guideline Update: Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer
28 Jan, 2021 | 01:17h | UTC
Preliminary study shows sitagliptin may prevent acute Graft-versus-Host Disease
26 Jan, 2021 | 00:35h | UTCDipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Sitagliptin promising addition for preventing acute GVHD – HealthDay
Cohort study: Aspirin linked to reduced risk of colon cancer if you start it before age 70
26 Jan, 2021 | 00:37h | UTCAspirin Use and Risk of Colorectal Cancer Among Older Adults – JAMA Oncology (free for a limited period)
Commentaries: Does aspirin lower colorectal cancer risk in older adults? It depends on when they start – Massachusetts General Hospital AND Aspirin Use Cuts CRC Risk in Those Initiating Use Before Age 70 – Physician’s Weekly
Randomized trial: In patients with colorectal peritoneal metastases, adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery does not improve survival and causes more frequent late complications
26 Jan, 2021 | 00:34h | UTCCytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
New online: PRODIGE 7 – #Cytoreductive #surgery plus hyperthermic intraperitoneal chemotherapy #HIPEC versus cytoreductive surgery alone for colorectal peritoneal metastases https://t.co/NuGwVmAnbt pic.twitter.com/NLk1DwwIXM
— The Lancet Oncology (@TheLancetOncol) January 19, 2021
NCCN shares new guidance principles for vaccinating people with cancer against COVID-19
26 Jan, 2021 | 00:47h | UTCOriginal guideline: Preliminary Recommendations of the NCCN COVID-19 Vaccination Advisory Committee
Commentary: NCCN Shares New Recommendations for Vaccinating Patients With Cancer Against COVID-19 – The ASCO Post
Global variation in postoperative mortality and complications after cancer surgery: a multicenter, prospective cohort study in 82 countries
25 Jan, 2021 | 01:21h | UTCCommentary: Better post-surgical care would boost cancer survival chances – University of Birmingham
Commentary on Twitter (thread – Click for more)
@GlobalSurg 3: Global variation in postoperative mortality & complications after cancer surgery, published in @TheLancet
16K patients underwent surgery across 82 countries.
Better postoperative care & facilities could significantly improve #cancer survivalhttps://t.co/QBRwGgyhLu pic.twitter.com/8f9T1N4O9i— Ewen Harrison (@ewenharrison) January 21, 2021
Randomized trial: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer
25 Jan, 2021 | 01:12h | UTCFirst-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: First-line Nivolumab and Ipilimumab Plus Chemotherapy Improves OS in NSCLC – AJMC
Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
25 Jan, 2021 | 01:13h | UTCFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
25 Jan, 2021 | 01:11h | UTC
Randomized trial of Irinotecan and Cetuximab with or without Vemurafenib in BRAF-Mutant metastatic colorectal cancer
22 Jan, 2021 | 07:57h | UTCCommentary: Triple chemotherapy combination improves metastatic colorectal cancer outcomes – SWOG AND Three Drugs Top Two for BRAF+ Metastatic Colorectal Cancer – MedPage Today
Final overall survival results of the IDEA Collaboration: 3 vs 6 months of adjuvant chemotherapy for Stage III Colon Cancer
22 Jan, 2021 | 07:58h | UTCOriginal article: Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Prospective analysis of 6 phase III trials on stage III colon cancer did not confirm non-inferior OS with 3 vs 6 months of adjuvant chemotherapy: the absolute difference in 5-yr OS was 0.4%, but reduced toxicities, inconvenience & costs may be important: https://t.co/mMjyRjeWyM
— NatureRevClinOncol (@NatRevClinOncol) December 2, 2020
Cohort study: Recipients of hematopoietic stem-cell transplantation who develop COVID-19 have poor overall survival
21 Jan, 2021 | 01:18h | UTC
[Abstract Only] Meta-analysis: Myelodysplastic syndrome and acute myeloid leukemia in patients treated with PARP inhibitors
21 Jan, 2021 | 00:37h | UTCMyelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: a safety meta-analysis of RCTs and a retrospective study of the WHO pharmacovigilance database shows an increased risk of myelodysplastic syndrome and acute myeloid leukaemia in patients treated w/ PARP inhibitors #MDSsm #leusm https://t.co/evYF1ozg6c
— The Lancet Haematology (@TheLancetHaem) December 21, 2020
An epidemic of overdiagnosis: Melanoma diagnoses sky rocket
20 Jan, 2021 | 01:30h | UTCAn epidemic of overdiagnosis: Melanoma diagnoses sky rocket – Brigham and Women’s Hospital AND Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? – Univadis
Original study: The Rapid Rise in Cutaneous Melanoma Diagnoses ($)
Related: Overdiagnosis: what it is and what it isn’t – BMJ Evidence Based Medicine (free) AND Overdiagnosis across medical disciplines: a scoping review – The BMJ Open (free) AND Too much medical care: bad for you, bad for health care systems – STAT News (free) AND Screening: How overdiagnosis and other harms can undermine the benefits – Health News Review (free) AND Overdiagnosis: causes and consequences in primary health care – Canadian Family Physician (free) AND Five warning signs of overdiagnosis – The Conversation (free) AND What is overdiagnosed cancer? And why does it matter? – Croakey (free) AND Blame rising cancer overdiagnosis on ‘irrational exuberance’ for early detection – STAT (free) AND Preventing overdiagnosis and the harms of too much sport and exercise medicine – British Journal of Sports Medicine (free)
Study: Similar length of hospital stay with laparoscopic vs. open gastrectomy for gastric cancer
20 Jan, 2021 | 01:05h | UTCLength of Hospital Stay With Laparoscopic vs Open Gastrectomy for Gastric Cancer – The ASCO Post
Meta-analysis: Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases
20 Jan, 2021 | 01:09h | UTC
IDH inhibitor Ivosidenib improves overall survival in previously treated patients with cholangiocarcinoma
20 Jan, 2021 | 01:08h | UTC
Postsurgical disease recurrence in stage I to III colorectal cancer may be predicted by ctDNA
20 Jan, 2021 | 01:07h | UTCCommentaries: Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA – The ASCO Post AND Liquid Biopsy Predicts Colon Cancer Relapse Months Before CT – MedPage Today (free registration required)
Randomized trial: Ultra-hypofractionated vs. conventionally fractionated radiotherapy for prostate cancer
19 Jan, 2021 | 01:14h | UTCUltra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)